Geoffrey M. Parker net worth and biography

Geoffrey Parker Biography and Net Worth

Executive Vice President, Chief Financial Officer of Allogene Therapeutics

Geoffrey (Geoff) Parker is the Executive Vice President, Chief Financial Officer of Allogene. He is a seasoned biotech and banking executive with nearly 40 years of leadership experience managing world-class finance and business development organizations. Geoff has directed and managed a broad range of strategic business and finance initiatives, including equity and debt financing, initial public offerings, and business development transactions. Prior to joining Allogene, Geoff served as Chief Operating Officer, Chief Financial Officer and Executive Vice President of Tricida, Inc., which focused on the development of an investigational drug candidate for metabolic acidosis in patients with chronic kidney disease. Prior to that, he served as Chief Financial Officer of Anacor Pharmaceuticals, which was acquired by Pfizer in 2016 for approximately $5.2 billion, and served as a Managing Director at Goldman Sachs, where he led the West Coast Healthcare Investment Banking group. In addition, Geoff currently serves as a member of the board of directors of Better Therapeutics and of Perrigo Company plc. He earned a B.A. with a double major in Economics and Engineering Sciences from Dartmouth College and an MBA from the Stanford Graduate School of Business.

What is Geoffrey M. Parker's net worth?: The estimated net worth of Geoffrey M. Parker is at least $25.02 thousand as of November 12th, 2025. Mr. Parker owns 17,375 shares of Allogene Therapeutics stock worth more than $25,020 as of December 5th. This net worth estimate does not reflect any other assets that Mr. Parker may own. Learn More about Geoffrey M. Parker's net worth.
How old is Geoffrey M. Parker?: Mr. Parker is currently 59 years old. There are 8 older executives and no younger executives at Allogene Therapeutics. The oldest executive at Allogene Therapeutics is Dr. Arie S. Belldegrun F.A.C.S., M.D., Co-Founder & Executive Chairman, who is 75 years old. Learn More on Geoffrey M. Parker's age.
How do I contact Geoffrey M. Parker?: The corporate mailing address for Mr. Parker and other Allogene Therapeutics executives is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Allogene Therapeutics can also be reached via phone at (650) 457-2700 and via email at [email protected]. Learn More on Geoffrey M. Parker's contact information.
Has Geoffrey M. Parker been buying or selling shares of Allogene Therapeutics?: During the past quarter, Geoffrey M. Parker has sold $46,297.44 in shares of Allogene Therapeutics stock. Most recently, Geoffrey M. Parker sold 36,744 shares of the business's stock in a transaction on Tuesday, October 21st. The shares were sold at an average price of $1.26, for a transaction totalling $46,297.44. Following the completion of the sale, the chief financial officer now directly owns 1,276,796 shares of the company's stock, valued at $1,608,762.96. Learn More on Geoffrey M. Parker's trading history.
Who are Allogene Therapeutics' active insiders?: Allogene Therapeutics' insider roster includes Rafael Amado (CMO), Arie Belldegrun (Director), Veer Bhavnagri (General Counsel), David Chang (President, Chief Executive Officer and Co-Founder), Earl Douglas (SVP), Franz Humer (Director), Stephen Mayo (Director), Geoffrey Parker (Executive Vice President, Chief Financial Officer), Zachary Roberts (Executive Vice President, Research & Development, Chief Medical Officer), Owen Witte (Director), and Annie Yoshiyama (SVP). Learn More on Allogene Therapeutics' active insiders.
Are insiders buying or selling shares of Allogene Therapeutics?: During the last year, insiders at the sold shares 10 times. They sold a total of 169,568 shares worth more than $294,129.46. The most recent insider tranaction occured on October, 21st when CFO Geoffrey M Parker sold 36,744 shares worth more than $46,297.44. Insiders at Allogene Therapeutics own 13.2% of the company. Learn More about insider trades at Allogene Therapeutics.
Information on this page was last updated on 10/21/2025.

Geoffrey M. Parker Insider Trading History at Allogene Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/21/2025	Sell	36,744	$1.26	$46,297.44	1,276,796
2/3/2025	Sell	4,361	$1.73	$7,544.53	1,301,540
1/30/2024	Buy	190	$3.60	$684.00	819,590

Geoffrey M. Parker Buying and Selling Activity at Allogene Therapeutics

Allogene Therapeutics Company Overview

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Today's Range

Now: $1.44

$1.41

$1.51

50 Day Range

MA: $1.28

$1.05

$1.52

2 Week Range

Now: $1.44

$0.86

$3.78

Volume

1,536,230 shs

Average Volume

2,359,507 shs

Market Capitalization

$323.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.47

Geoffrey Parker Biography and Net Worth

What is Geoffrey M. Parker's net worth?

How old is Geoffrey M. Parker?

How do I contact Geoffrey M. Parker?

Has Geoffrey M. Parker been buying or selling shares of Allogene Therapeutics?

Who are Allogene Therapeutics' active insiders?

Are insiders buying or selling shares of Allogene Therapeutics?